The United States Food and Drug Administration (FDA) has granted approval to United States-based Pfizer for the subcutaneous use of Fragmin (dalteparin sodium) injection intended for the treatment of potentially life-threatening blood clots in paediatric patients, it was reported on Friday.
The latest approval for the product is for the blood thinner to be used to decrease symptomatic venous thromboembolism in paediatric patients, aged one month and older.
Its efficacy in children was demonstrated in a single trial with 38 paediatric patients having symptomatic deep vein thrombosis and/or pulmonary embolism. In the trial, patients were subjected to the product for up to three months, with starting doses based on age and weight. After completion of the study, 21 patients achieved resolution of the qualifying venous thromboembolism, while seven patients had regression. Two patients did not show any change, while no patients had progression of the venous thromboembolism and one patient had recurrence of the condition.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT